mirvetuximab
immunogen
['mirasol', 'mirvetuximab', 'gyn']
join at 7:30am cdt in an oral abstract session on #gynecologiccancer to hear an initial report of the phase 3 mirasol study of mirvetuximab soravtansine: #asco23 #crukfunded 
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK